Caffeine
May improve performance in specific tasks; weigh benefits against anxiety and sleep loss.
What it is for
Strength and endurance performance, focus and a lower perception of effort.
How it works
An adenosine receptor antagonist: it reduces the sensation of fatigue and increases central nervous system activation.
Dosing
In healthy adults, start low. EFSA identifies up to 200 mg per dose and 400 mg/day from all sources as generally not raising safety concerns; these are not targets or individual guarantees. Sports doses of 3–6 mg/kg can exceed these reference amounts.
When to take it
30–60 min before training. Avoid within 8–9 h of bedtime.
Safety
Safe at moderate doses. High doses: anxiety, tachycardia, insomnia.
Side effects
Jitteriness, stomach discomfort, disrupted sleep, mild dependence.
Interactions
It adds to other stimulants; be careful with heavily loaded pre-workouts.
Contraindications
Arrhythmias, uncontrolled hypertension, anxiety, pregnancy (limit to <200 mg/day).
Who it has been studied in
Response depends on dose, sleep, habitual use and other factors. A single genotype cannot reliably predict individual benefit.
Frequently asked
Do you build a tolerance?
Habituation can occur, but stopping does not guarantee renewed ergogenic effects and may cause withdrawal. Routine cycling is unnecessary.
Does it dehydrate you?
The diuretic effect is mild and well tolerated; it is not a practical problem when training.
What this rests on
Wake up and smell the coffee: caffeine supplementation and exercise performance — an umbrella review of 21 published meta-analyses
Grgic J, Grgic I, Pickering C, et al. · 2019 · British Journal of Sports Medicine
Effect: A small-to-moderate effect on muscular strength/power and also on aerobic endurance, consistent across the 21 meta-analyses reviewed.
Limitations: Response varies with genetics (caffeine metabolism) and tolerance from habitual intake; most studies use a single laboratory dose, not real daily consumption patterns.
- Evidence tier
- A
- Quality
- High
- Studies
- >100 RCTs, umbrella reviews
- Consensus
- ISSN position in favor
- Controversy
- Effect size varies with genetics (CYP1A2) and habituation
- Reviewed
- 2024
Strength of evidence out of 5.